Title : Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib.

Pub. Date : 2013 Jun

PMID : 23442043






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 To date, pacritinib (SB1518), a selective JAK2/FLT3 inhibitor is the first and only JAK inhibitor that has been evaluated in patients with relapsed lymphoma. 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene fms related receptor tyrosine kinase 3 Homo sapiens
2 To date, pacritinib (SB1518), a selective JAK2/FLT3 inhibitor is the first and only JAK inhibitor that has been evaluated in patients with relapsed lymphoma. 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene fms related receptor tyrosine kinase 3 Homo sapiens